Alkermes plc. — fact timeline

Alkermes plc. shareholders approved Renewal of Board authority to disapply statutory pre-emption rights under Irish law at the 2026-05-20 meeting.

“Shareholders renewed Board authority to disapply the statutory pre-emption rights that would otherwise apply under Irish law, with the votes cast as follows: 146,903,611 votes for; 2,086,009 votes against; and 91,983 votes abstaining.”

Alkermes plc. shareholders approved Renewal of Board authority to allot and issue shares under Irish law at the 2026-05-20 meeting.

“Shareholders renewed Board authority to allot and issue shares under Irish law, with the votes cast as follows: 148,661,934 votes for; 382,138 votes against; and 37,531 votes abstaining.”

Alkermes plc. shareholders approved Approval of the 2018 Plan at the 2026-05-20 meeting.

“Shareholders approved the 2018 Plan, with the votes cast as follows: 128,147,910 votes for; 12,952,836 votes against; 69,229 votes abstaining; and 7,911,628 broker non-votes.”

Alkermes plc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent auditor at the 2026-05-20 meeting.

“Shareholders ratified, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company, and authorized, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm’s remuneration, with the votes cast as follows: 146,222,286 votes for; 2,812,663 votes against; and 46,653 votes abstaining.”

Alkermes plc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2026-05-20 meeting.

“Shareholders approved, in a non-binding, advisory vote, the compensation of the Company’s named executive officers, with the votes cast as follows: 139,234,176 votes for; 1,787,311 votes against; 148,488 votes abstaining; and 7,911,628 broker non-votes.”

Alkermes plc. shareholders approved Election of directors at the 2026-05-20 meeting.

“By separate resolutions, shareholders elected the following directors, each to serve on the Company’s board of directors (the “Board”) for a one-year term until the Company’s 2027 annual general meeting of shareholders, with the votes cast as follows:”

Alkermes plc. reported the three months ended March 31, 2026 results: revenue $392.9 Million, net income GAAP Net Loss of $66.5 Million. Guidance lowered.

“Alkermes plc Reports First Quarter 2026 Financial Results — First Quarter Revenues of $392.9 Million; GAAP Net Loss of $66.5 Million and Adjusted EBITDA of $80.3 Million”

Alkermes plc. amended credit facility.

“On February 12, 2026, we terminated the previously disclosed Bridge Credit Agreement”

Alkermes plc. incurred term loan of up to $775 million with JPMorgan Chase Bank, N.A., as Administrative Agent, Joint Lead Arranger and Joint Bookrunner, BofA Securities, Inc., as Joint Lead Arranger and Joint Bookrunner, and the lenders party thereto at Term SOFR Rate plus a margin of 2.75% per annum or the Alternate Base Rate plus maturing August 12, 2031.

“a senior secured term loan B facility in an aggregate principal amount of up to $775 million (the "TLB Facility" and together with the TLA Facility, the "Facilities").”

Alkermes plc. incurred term loan of up to $750 million with JPMorgan Chase Bank, N.A., as Administrative Agent, Joint Lead Arranger and Joint Bookrunner, BofA Securities, Inc., as Joint Lead Arranger and Joint Bookrunner, and the lenders party thereto at Term SOFR Rate plus a Secured Net Leverage Ratio-based margin, which will initia maturing February 12, 2031.

“The Credit Agreement provides for (i) a senior secured term loan A facility in an aggregate principal amount of up to $750 million (the "TLA Facility")”

Alkermes plc. entered into Credit Agreement with JPMorgan Chase Bank, N.A., as Administrative Agent, Joint Lead Arranger and Joint Bookrunner, BofA Securities, Inc., as Joint Lead Arranger and Joint Bookrunner, and the lenders party thereto valued at $1.525 billion (effective 2026-02-12).

“On February 12, 2026, in connection with the Acquisition (as defined below), Alkermes plc (the “Company”) entered into a credit agreement (the “Credit Agreement”), by and among Alkermes plc, as the TopCo Borrower, Alkermes, Inc., as the U.S. Borrower, Alkermes Finance LLC, as the U.S. Co-Borrower, JPMorgan Chase Bank, N.A., as Administrative Agent, Joint Lead Arranger and Joint Bookrunner, BofA Securities, Inc., as Joint Lead Arranger and Joint Bookrunner, and the lenders party thereto.”

Alkermes plc. completed an acquisition involving Avadel Pharmaceuticals plc for $21.00 in cash, plus one non-transferable contingent value right representing a potential additional cash payment of $1.50 per Avadel Share (closed 2026-02-12).

“Shares outstanding as of 11:59 p.m., New York City time, on February 11, 2026, the business day prior to the occurrence of the Effective Time, became entitled to receive (i) $21.00 in cash (the “Cash Consideration”) for each Avadel Share and (ii) one non-transferable contingent value right (a “CVR”) for each Avadel Share, in each case in accordance with the”

Alkermes plc. amended credit facility of up to $1,512,562,923.28 with JPMorgan Chase Bank, N.A. at Term SOFR Rate plus a margin of 3.00% per annum or Alternate Base Rate plus a ma maturing 364 days after the date on which the loans are funded under the Bridge Credit Facility.

“The Amended and Restated Bridge Credit Agreement increased commitments from those provided under the Existing Bridge Credit Agreement and, after giving effect to the increase, provides for a senior secured bridge term loan facility (the “Bridge Credit Facility”) in an aggregate principal amount of up to $1,512,562,923.28 that is available to finance the payment of Cash Consideration and fees and expenses related to the Acquisition. The commitments under the Bridge Credit Facility will be reduced by the net cash proceeds received by Alkermes or its subsidiaries in connection with debt and equity issuances and non-ordinary course asset dispositions, with certain exceptions specified in the Amended and Restated Bridge Credit Agreement. Loans under the Bridge Credit Facility will be available after the Amendment Date, subject to the satisfaction of certain conditions set forth in the Amended and Restated Bridge Credit Agreement, and will mature on the date that is 364 days after the date o”

Alkermes plc. incurred credit facility.

“On the Agreement Date, Alkermes entered into the Bridge Credit Agreement as described under Item 1.01 above.”

Alkermes plc. updated its first quarter of 2024 guidance (reaffirmed).

“On May 1, 2024, Alkermes plc (the “Company”) announced financial results for the three months ended March 31, 2024.”

Nancy S. Lurker was elected as Director at Alkermes plc..

“Effective March 5, 2024, the board of directors (the “Board”) of Alkermes plc (the “Company”) increased the size of the Board to eleven (11) directors and elected Nancy S. Lurker to the Board, with an initial term expiring at the Company’s 2024 annual general meeting of shareholders (the “2024 Annual Meeting”).”

Alkermes plc. reported the quarter and year ended Dec. 31, 2023 results: revenue $1,663.4 million, net income $355.8 million, EPS $2.10. Guidance initiated.

“Joyce +1 781 249 8927 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 — Total Revenues of $1.66 Billion in 2023; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income of $356 Million and Diluted GAAP Earnings per Share of $2.10 for 2023 —”

Samuel J. Parisi was appointed as Interim Principal Accounting Officer at Alkermes plc..

“and Samuel J. Parisi, Vice President, Finance of Alkermes, Inc., as the Company's interim principal accounting officer”

Blair C. Jackson was appointed as Interim Principal Financial Officer at Alkermes plc..

“designated Blair C. Jackson, Executive Vice President, Chief Operating Officer of Alkermes, Inc., a wholly-owned subsidiary of the Company, as the Company's interim principal financial officer”

Alkermes plc. entered into Purchase Agreement with Novo Nordisk Production Ireland Limited and Novo Nordisk A/S valued at $92.5 million (effective 2023-12-13).

“On December 13, 2023, Alkermes Pharma Ireland Limited (the “Seller”), an indirect wholly-owned subsidiary of Alkermes plc (together with its subsidiaries, the “Company”), entered into an asset purchase agreement (the “Purchase Agreement”) with Novo Nordisk Production Ireland Limited (the “Purchaser”) and Novo Nordisk A/S (the “Purchaser Guarantor” and, collectively with the Seller and the Purchaser, the “Parties”).”

Frank Anders Wilson was appointed as Lead Independent Director at Alkermes plc..

“appointed Frank Anders Wilson as the Lead Independent Director of the Board, in each case effective as of December 8, 2023.”

Nancy J. Wysenski retired as director at Alkermes plc..

“On December 4, 2023, following ten years of service, Nancy J. Wysenski notified Alkermes plc (the “Company”) of her decision to retire, for personal reasons, from the Company’s board of directors (the “Board”) and from any Board leadership positions and committees on which she serves, in each case effective as of December 8, 2023.”

Alkermes plc. completed a disposition involving Mural Oncology plc (closed 2023-11-15).

“on November 15, 2023, the Company completed the Separation and the Distribution.”

Alkermes plc. updated its three and nine months ended September 30, 2023 guidance (reaffirmed).

“On October 25, 2023, Alkermes plc (the “Company”) announced financial results for the three and nine months ended September 30, 2023.”

Alkermes plc. entered into Confidential Settlement and License Agreement with Teva Pharmaceuticals USA, Inc. (effective 2023-08-29).

“On August 29, 2023, Alkermes, Inc. and Alkermes Pharma Ireland Limited, subsidiaries of Alkermes plc (together, “Alkermes”), entered into a Confidential Settlement and License Agreement (the “Settlement Agreement”) with Teva Pharmaceuticals USA, Inc. (“Teva”, and together with Alkermes, the “parties”) relating to Alkermes’ product VIVITROL ® (naltrexone for extended-release injectable suspension).”

Alkermes plc. updated its three and six months ended June 30, 2023 guidance (reaffirmed).

“On July 26, 2023, Alkermes plc (the “Company”) announced financial results for the three and six months ended June 30, 2023.”

Alkermes plc. shareholders approved Renewal of Board authority to disapply statutory pre-emption rights under Irish law at the 2023-06-29 meeting.

“6. Shareholders renewed Board authority to disapply the statutory pre-emption rights that would otherwise apply under Irish law, with the votes cast as follows: 111,942,236 votes for; 34,750,182 ** votes against; and 294,360 votes abstaining.”

Alkermes plc. shareholders approved Renewal of Board authority to allot and issue shares under Irish law at the 2023-06-29 meeting.

“5. Shareholders renewed Board authority to allot and issue shares under Irish law, with the votes cast as follows: 131,189,831 votes for; 15,574,774 ** votes against; and 222,173 votes abstaining.”

Alkermes plc. shareholders approved Approval of the 2018 Plan (equity incentive plan) at the 2023-06-29 meeting.

“4. Shareholders approved the 2018 Plan, with the votes cast as follows: 125,407,407 votes for; 21,308,908 ** votes against; and 270,463 votes abstaining.”

Alkermes plc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent auditor and authorization of Audit and Risk Committee to set remuneration at the 2023-06-29 meeting.

“3. Shareholders ratified, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company, and authorized, in a binding vote, the Audit and Risk Committee of the Board of Directors of the Company (the “Board”) to set the independent auditor and accounting firm’s remuneration, with the votes cast as follows: 142,558,190 votes for; 4,308,181 votes against; and 120,407 votes abstaining.”

Alkermes plc. shareholders approved Advisory vote on executive compensation at the 2023-06-29 meeting.

“2. Shareholders approved, in a non-binding, advisory vote, the compensation of the Company’s named executive officers, with the votes cast as follows: 115,881,199 votes for; 30,815,867 * votes against; and 289,712 votes abstaining.”

Alkermes plc. shareholders approved Re-election of directors for a one-year term expiring at the 2024 annual general meeting at the 2023-06-29 meeting.

“On June 29, 2023, the Company held its Annual Meeting. Based on the certified voting report provided by the inspector of elections for the Annual Meeting, the final voting results are as follows: 1. Shareholders re-elected the following directors, each to serve as a director for a one-year term expiring at the Company’s 2024 annual general meeting of shareholders or until their respective successor is elected and shall qualify, with the votes cast as follows: For: Withheld: Emily Peterson Alva 133,264,886 13,721,892 ** Shane M. Cooke 109,649,902 37,336,876 * Richard B. Gaynor, M.D. 85,056,971 61,929,807 * Cato T. Laurencin, M.D., Ph.D. 132,349,967 14,636,811 ** Brian P. McKeon 133,130,612 13,856,166 ** Richard F. Pops 107,961,225 39,025,553 * Christopher I. Wright, M.D., Ph.D. 132,681,062 14,305,716 **”

Alkermes plc. amended Amendment with Morgan Stanley Senior Funding, Inc., as administrative agent and collateral agent, and the financial institutions and entities party thereto as lenders (effective 2023-06-28).

“On June 28, 2023, Alkermes, Inc., a subsidiary of Alkermes plc (the “Company”), entered into an amendment (the “Amendment”) to the Amended and Restated Credit Agreement, dated as of September 16, 2011 and amended and restated on September 25, 2012, as further amended by Amendment No. 2 on February 14, 2013, Amendment No. 3 and Waiver on May 22, 2013, Amendment No. 4 on October 12, 2016, Amendment No. 5 on March 26, 2018, and Amendment No. 6 on March 12, 2021 (the “Credit Agreement”), by and among Morgan Stanley Senior Funding, Inc., as administrative agent and collateral agent, and the financial institutions and entities party thereto as lenders.”

Alkermes plc. reported three months ended March 31, 2023 results: revenue $287.6 million, net income $41.8 million, EPS $0.25 loss per share. Guidance reaffirmed.

“Alkermes plc Reports First Quarter 2023 Financial Results — First Quarter Revenues of $287.6 Million Reflect Strong Performance of Proprietary Product Portfolio — — GAAP Loss per Share of $0.25 and Basic and Diluted Non-GAAP Earnings per Share of $0.01 — — Planned Separation of Oncology Business Expected to be Completed in Second Half of 2023 — — Second Favorable Interim Award Received in Janssen Arbitration — — Financial Expectations for 2023 Reiterated —”

Alkermes plc. updated its the year ending December 31, 2023 guidance (initiated).

“On February 16, 2023, Alkermes plc (the “Company”) announced financial results for the three months and year ended December 31, 2022 and financial expectations for the year ending December 31, 2023.”

Alkermes plc. reported the year ended December 31, 2022 results: revenue $1.11 billion, net income $158.3 million, EPS $0.97.

“— Revenues of $1.11 Billion in 2022, GAAP Loss per Share of $0.97 and Diluted Non-GAAP Earnings per Share of $0.34 —”

Alkermes plc. reported the quarter ended December 31, 2022 results: revenue $304.7 million, net income $28.3 million, EPS $0.17.

“• Total revenues for the quarter were $304.7 million, compared to $324.5 million for the same period in the prior year. • Net sales of proprietary products for the quarter were $216.1 million, compared to $178.9 million for the same period in the prior year. o Net sales of VIVITROL were $102.0 million, compared to $92.0 million for the same period in the prior year, representing an increase of approximately 11%. o Net sales of ARISTADA 1 were $79.2 million, compared to $78.7 million for the same period in the prior year, representing an increase of approximately 1%. o Net sales of LYBALVI were $34.9 million, compared to $8.2 million for the same period in the prior year, following commercial launch in October 2021. • Total operating expenses for the quarter were $325.3 million, compared to $322.1 million for the same period in the prior year. • Net loss according to generally accepted accounting principles in the U.S. (GAAP) was $28.3 million for the quarter, or a basic and”

Alkermes plc. reported the year ending December 31, 2022 results: revenue $1,070 – $1,120. Guidance raised.

“to GAAP, except as otherwise noted. In millions (except per share amounts) Current 2022 Expectation (Provided 11/2/22) Prior 2022 Expectation (Provided 7/27/22) Total Revenue $1,070 – $1,120 $1,050 – $1,120 VIVITROL Net Sales $370 – $380 $365 – $385 ARISTADA Net Sales $300 – $310 $295 – $315 LYBALVI Net Sales $88 – $”

Alkermes plc. reported the third quarter of 2022 results: revenue $252.4 million, net income $64.0 million, EPS $0.39.

“— Third Quarter Revenues of $252.4 Million Reflect Strong Year-Over-Year Growth of Proprietary Commercial Product Portfolio — — GAAP Loss per Share of $0.39 and Non-GAAP Earnings per Share of $0.02 —”

Christopher I. Wright was elected as Director at Alkermes plc..

“the Board elected Dr. Christopher I. Wright to the Board, effective immediately”

Wendy L. Dixon departed as Director at Alkermes plc..

“David W. Anstice AO and Wendy L. Dixon, Ph.D. notified Alkermes plc (the “Company”) of their decision to retire from the Company’s board of directors (the “Board”) and from any committees of the Board on which they serve”

David W. Anstice AO departed as Director at Alkermes plc..

“David W. Anstice AO and Wendy L. Dixon, Ph.D. notified Alkermes plc (the “Company”) of their decision to retire from the Company’s board of directors (the “Board”) and from any committees of the Board on which they serve”

Dr. Cato T. Laurencin was elected as Director at Alkermes plc..

“On November 18, 2021, the Board of Directors (the “Board”) of Alkermes plc (the “Company”) increased the size of the Board to twelve (12) directors and elected Dr. Cato T. Laurencin to the Board, effective immediately, as a Class II member with a term expiring at the Company’s 2022 annual general meeting of shareholders.”